GlaxoSmithKline plc (UK) (GB:GSK) has released an update.
GlaxoSmithKline plc has reported a robust start to 2024, with a 10% increase in sales to £7.4 billion, excluding COVID-related solutions. The pharmaceutical giant witnessed significant growth in its Vaccines and Specialty Medicines units, with notable sales from its newly launched vaccines Arexvy and Ojjaara. Cash generated from operations exceeded £1 billion, demonstrating strong financial performance and operational efficiency. GSK’s updated 2024 guidance reflects a positive outlook, with turnover growth expected towards the upper end of the 5% to 7% range and Core EPS growth anticipated to be between 8% to 10%.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
